Coprelotamab Biosimilar – Anti-ERBB2 mAb – Research Grade from ProteoGenix; catalogue PX-TA1650; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Coprelotamab Biosimilar: A Promising Anti-ERBB2 Monoclonal Antibody for
Coprelotamab Biosimilar, also known as Anti-ERBB2 mAb, is a monoclonal antibody that has shown promising results in the treatment of various types of cancers. It is a biosimilar of Trastuzumab, a widely used therapeutic antibody targeting the human epidermal growth factor receptor 2 (HER2 or ERBB2). Coprelotamab Biosimilar is designed to specifically bind to HER2 and inhibit its activity, thereby preventing cancer cell growth and proliferation.
Coprelotamab Biosimilar is a recombinant humanized monoclonal antibody, meaning it is produced in the laboratory using genetic engineering techniques. It is composed of two identical heavy chains and two identical light chains, connected by disulfide bonds. The heavy chains consist of constant and variable regions, while the light chains only have variable regions. The variable regions of both chains contain complementarity-determining regions (CDRs) that determine the specificity of the antibody for its target.
The constant region of Coprelotamab Biosimilar is derived from human IgG1, making it less immunogenic and more compatible with human immune system. This also allows for better effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which are important mechanisms for cancer cell killing.
Coprelotamab Biosimilar works by binding to HER2 on the surface of cancer cells, preventing the binding of its natural ligands and disrupting downstream signaling pathways. HER2 is a receptor tyrosine kinase that is overexpressed in many types of cancers, including breast, ovarian, and gastric cancer. Its overexpression is associated with aggressive tumor growth and poor prognosis. By targeting HER2, Coprelotamab Biosimilar inhibits cancer cell proliferation, induces cell death, and enhances the immune response against cancer cells.
In addition, Coprelotamab Biosimilar can also activate the immune system to attack cancer cells through ADCC and CDC. When the antibody binds to HER2, the constant region of the antibody interacts with immune cells, such as natural killer (NK) cells and macrophages, triggering them to release cytotoxic substances and kill the cancer cells.
Coprelotamab Biosimilar is currently being evaluated in clinical trials for the treatment of HER2-positive breast cancer, gastric cancer, and other solid tumors. It has shown promising results in combination with chemotherapy and other targeted therapies, such as Pertuzumab and Lapatinib. In addition, it is also being investigated as a potential treatment for HER2-positive metastatic breast cancer that has become resistant to Trastuzumab.
Furthermore, Coprelotamab Biosimilar has the potential to be used as a biosimilar of Trastuzumab in countries where the latter is not available or affordable. This can increase access to effective cancer treatment and potentially reduce healthcare costs.
Coprelotamab Biosimilar is a promising anti-HER2 monoclonal antibody with a similar structure and mechanism of action as Trastuzumab. It has the potential to improve the treatment outcomes of HER2-positive cancers and provide an affordable option for patients in need. Further clinical studies are needed to fully evaluate its efficacy and safety, but the early results are encouraging. Coprelotamab Biosimilar has the potential to be a valuable addition to the arsenal of cancer therapeutics and improve the lives of cancer patients worldwide.
ProteoGenix catalogue number PX-TA1650. For research use only.
Target: Coprelotamab Biosimilar – Anti-ERBB2 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Coprelotamab Biosimilar – Anti-ERBB2 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
